AZN.UK

11,090

-2.99%↓

HLN.UK

386.5

-2.15%↓

INDV

727.5

-0.34%↓

AZN.UK

11,090

-2.99%↓

HLN.UK

386.5

-2.15%↓

INDV

727.5

-0.34%↓

AZN.UK

11,090

-2.99%↓

HLN.UK

386.5

-2.15%↓

INDV

727.5

-0.34%↓

AZN.UK

11,090

-2.99%↓

HLN.UK

386.5

-2.15%↓

INDV

727.5

-0.34%↓

AZN.UK

11,090

-2.99%↓

HLN.UK

386.5

-2.15%↓

INDV

727.5

-0.34%↓

Search

GlaxoSmithKline PLC

Atidarymo kaina

SektoriusSveikatos priežiūra

1,423.5 -4.37

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1413.5

Max

1492.5

Pagrindiniai rodikliai

By Trading Economics

Pajamos

559M

501M

Pardavimai

105M

8.1B

P/E

Sektoriaus vid.

23.581

73.239

Pelnas, tenkantis vienai akcijai

0.232

Dividendų pajamingumas

4.3

Pelno marža

6.172

Darbuotojai

68,629

EBITDA

-52M

1.1B

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+8.98% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

4.30%

3.06%

Kitas uždarbis

2025-04-30

Kitas dividendų mokėjimo data

2025-04-10

Kita Ex Dividend data

2025-05-15

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-586M

59B

Ankstesnė atidarymo kaina

1427.87

Ankstesnė uždarymo kaina

1423.5

Naujienos nuotaikos

By Acuity

40%

60%

138 / 386 reitingas Healthcare

GlaxoSmithKline PLC Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-02-05 11:32; UTC

Uždarbis

GSK Launches $2.5 Billion Buyback, Raises Midterm Sales Outlook -- 2nd Update

2025-02-05 08:56; UTC

Uždarbis

Correction to GSK Article

2025-02-05 08:24; UTC

Uždarbis

GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After Beating Market Views -- Update

2025-02-05 07:43; UTC

Uždarbis

GSK Expects Further Profit Growth After Beating Market Views

2025-01-13 07:14; UTC

Įsigijimai, susijungimai, perėmimai

GSK to Buy U.S. Rare Tumor Specialist IDRx for Up to $1.15 Billion

2025-03-26 22:29; UTC

Svarbiausios naujienos

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- 2nd Update

2025-03-26 19:19; UTC

Svarbiausios naujienos

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- Update

2025-03-26 17:39; UTC

Svarbiausios naujienos

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- WSJ

2025-03-19 14:50; UTC

Svarbiausios naujienos

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

2025-03-17 09:00; UTC

Svarbiausios naujienos

Pfizer Has a New Playbook for Reviving Sales -- And It's Starting to Pay Off -- WSJ

2025-02-24 07:05; UTC

Įsigijimai, susijungimai, perėmimai

GSK Completes Acquisition of IDRx

2025-02-14 11:38; UTC

Svarbiausios naujienos
Uždarbis

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

2025-02-14 11:30; UTC

Svarbiausios naujienos
Uždarbis

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

2025-02-05 15:33; UTC

Rinkos pokalbiai
Uždarbis

GSK's Pipeline Has to Prove It Can Counter Concerns Over Vaccine Business -- Market Talk

2025-02-05 08:38; UTC

Rinkos pokalbiai
Uždarbis

GSK Needs to Show It Can Navigate Vaccines Challenge -- Market Talk

2025-02-05 07:05; UTC

Uždarbis

GSK PLC Had Seen 2031 Sales Outlook at More Than GBP38B

2025-02-05 07:04; UTC

Uždarbis

GSK PLC Sees 2031 Sales Outlook at More Than GBP40B

2025-02-05 07:03; UTC

Uždarbis

GSK PLC Sees 2025 Adjusted EPS Growth of 6%-8%

2025-02-05 07:03; UTC

Uždarbis

GSK PLC Raises Mid-Term View

2025-02-05 07:03; UTC

Uždarbis

GSK PLC Sees 2025 Adjusted Operating Growth of 6% - 8%

2025-02-05 07:02; UTC

Uždarbis

GSK PLC Sees 2025 Turnover Growth of 3% to 5%

2025-02-05 07:02; UTC

Uždarbis

GSK PLC Issues GBP2B Buyback

2025-02-05 07:01; UTC

Uždarbis

GSK PLC Declares 4Q Dividend of 16p

2025-02-05 07:00; UTC

Uždarbis

GSK PLC 4Q Core EPS Consensus Was 20.6p

2025-02-05 07:00; UTC

Uždarbis

GSK PLC 4Q Sales Consensus Was GBP7.83B

2025-02-05 07:00; UTC

Uždarbis

GSK PLC 4Q Pretax Pft GBP563M

2025-02-05 07:00; UTC

Uždarbis

GSK PLC 4Q EPS 10.0p

2025-02-05 07:00; UTC

Uždarbis

GSK PLC 4Q Adj EPS 23.2p

2025-02-05 07:00; UTC

Uždarbis

GSK PLC 4Q Oper Pft GBP696M

2025-01-13 07:05; UTC

Įsigijimai, susijungimai, perėmimai

GSK Enters Agreement To Acquire IDRx, Inc. >GSK.LN

Akcijų palyginimas

Kainos pokytis

GlaxoSmithKline PLC Prognozė

Kainos tikslas

By TipRanks

8.98% į viršų

12 mėnesių prognozė

Vidutinis 1,593.33 GBX  8.98%

Aukščiausias 2,290 GBX

Žemiausias 1,450 GBX

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines GlaxoSmithKline PLC kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

12 ratings

2

Pirkti

8

Laikyti

2

Parduoti

Rinkos nuotaikos

By Acuity

138 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.